34 results about "Deep fungal infection" patented technology

The invention relates to a thiochromone compound, which has the structure as right: wherein R1 is five-membered nitrogen-containing aromatic heterocycle substituted by hydrogen, methyl, nitryl or cyano; R2 is aliphatic alkyl of C1 to C12 or unsubstituted five-membered or six-membered aromatic ring aliphatic alkyl or five-membered or six-membered aromatic ring aliphatic alkyl selectively substituted by amino group, methyl, trifluoromethyl, trifluoromethoxy, nitryl, halogen and cyano; R3 is alkyl, hydrogen, fluorine, chlorine, bromine or iodine of C1 to C4; R4 is hydrogen, fluorine, chlorine, bromine, iodine or five-membered or six-membered heterocycle containing nitrogen; and R5 and R6 are hydrogen, fluorine, chlorine, bromine, iodine, alkyl of C1 to C4, hydroxyl, oxyl of C1 to C4, cyano, nitryl, amino group or amino group substituted by alkyl of C1 to C4. The compound has application in preparing antifungal medicaments, strong bacteriostatic activity for common pathogenic fungus and deep fungal infection, low toxicity, good stability and broad antifungal spectrum.

The invention relates to a novel broad-spectrum antifungal medicine compound, a broad-spectrum antifungal medicine composition, an application of the compound or the composition in the preparation of a broad-spectrum antifungal medicine, and an application of the compound or the composition in the preparation of a medicine used for treating severe invasive infection (comprising Candida krusei) caused by invasive aspergillosis and / or Fluconazole-resistant Monilia and / or severe infection caused by Scedosporium and fusarium. The novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have extensive and strong antifungal activity and better dynamic property and safety. For deep mycotic infection, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition are better than the original voriconazole in the aspects of the antibiotic activity and the medicine resistance and is better than amphotericin B in the aspects of safety and effectiveness; and compared with the formerly applied voriconazole, Fluconazole, itraconazole and amphotericin B, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have reinforced medicine effect, less adverse reaction and good safety.

The invention discloses a terbinafine nanometer antifungal which is prepared by terbinafine, oil, surfactant, water according to the following method: First, the said raw materials are unloaded and weighed and reserved, then surfactants and oil is blended and mixed; terbinafine is added into cosurfactant and completely dissolved; the solution with terbinafine dissolved in it is added to the homogeneous mixed surfactant and oil, stirring uniform, finally, distilled water is slowly added dropwise, dropwising and stirring until the stable, homogeneous, transparent terbinafine nanometer antifungal is obtained. The drug with small particles, small viscosity, good fluidity and good nature stability, can reach through the skin and get into the blood circulation, inhibit squalene cycloxygenase, so as to treat the dermatophyte infection and many deep mycotic infection with a drastic therapeutic effect, and what is more the preparation of the invented products is simple, low energy consumption and without special equipment the drug can be mass produced.

The present disclosure relates to methods and devices for amplifying a plurality of targets in a single PCR run while distinguishing between clinically relevant amplification and amplification from other sources such as from background contamination. The methods and devices further enable discrimination between gram-positive, gram-negative and fungal infections as wells as identify antimicrobial resistance genes. When applying the methods and devices of the invention, the species or genus of an infection(s), and genus of a fungal co-infection(s) or category of bacterial (gram-positive or negative) co-infection(s) are identified. Species identification of co-infections can also be achieved. Further, when applying the methods and devices of the invention, organisms which are likely to be contaminating organisms from a blood draw are identified.

The present disclosure relates to methods and devices for amplifying a plurality of targets in a single PCR run while distinguishing between clinically relevant amplification and amplification from other sources such as from background contamination. The methods and devices further enable discrimination between gram-positive, gram-negative and fungal infections as wells as identify antimicrobial resistance genes. When applying the methods and devices of the invention, the species or genus of an infection(s), and genus of a fungal co-infection(s) or category of bacterial (gram-positive or negative) co-infection(s) are identified. Species identification of co-infections can also be achieved. Further, when applying the methods and devices of the invention, organisms which are likely to be contaminating organisms from a blood draw are identified.

The invention relates to the medical technology field, and discloses an application of lysine as a synergist for preparing antifungal drugs like polyenes or echinocandins. The antifungal drugs may be amphotericin B, nystatin or caspofungin. The amount of lysine or pharmaceutically acceptable salts thereof in the antifungal drug effective concentration is 0.03-0.5mM. As shown in an experiment, the combination application of antifungal drugs like amphotericin B, nystatin and caspofungin, can also ensure the treatment effect on superficial and deep fungal infections in case of decrease of drug dose, and the combination can be used as a synergist of the antifungal drugs. The lysine, as the synergist of the antifungal drugs, can decrease the medical dosage of the antifungal drugs like polyenes or echinocandins, thereby alleviating the toxic and side effect of medicaments, effectively treating fungal infection, and having a high application value.

The invention provides a voriconazole suppository and a preparation method and application thereof. The suppository comprises an effective dose of voriconazole, a dispersion carrier and a matrix, wherein the matrix comprises a forming agent, an emulsifying agent and a suspension aid agent. The preparation method comprises the following steps of: dissolving or dispersing voriconazole in the dispersion carrier, and uniformly mixing with the molten matrix to obtain the suppository; or adding the dispersion carrier into the molten matrix, and adding the voriconazole powder and the suspension aid agent, and uniformly mixing to obtain the suppository. The voriconazole suppository is applied to rectal or gynecological cavity administration and to the therapy for local or whole-body deep fungus infection. The invention provides a safe and effective cavity or rectal administration drug form which avoids the first-pass effect of liver, directly reaches the focus, reduces the medicine dosage, isparticularly suitable for the therapy for local deep fungus infection in gynecological cavity, pelvic cavity, accessory and the like, and ensures little side effect and good curative effect.

The invention relates to the field of medicine technology and is especially new use of shikonin as an antifungal medicine synergist. The antifungal medicine comprises azole or polyene antifungal medicine and the like, the charge of shikonin is 1-16 mu g / ml in the antifungal medicine. Experiments show that when shikonin is used with the antifungal medicines such as fluconazole, ketoconazole, miconazole or amphotericin B and the like, the treatment effect of superfacial or deep fungal infection can be ensured under the circumstances of reduction of dosage, and the effects of the antifungal medicines to resistant fungi are recovered, thereby that shikonin can be used as antifungal medicine synergist with the advantages of reducing dosages of azole or polyene antifungal medicine so as to reduce side effects of medicines, especially recovering the effects of the antifungal medicines to resistant fungi to treat resistant fungal infection, and having important clinical application value.

The invention discloses a technology for purifying medicines for treating deep fungal infection. The technology is characterized in that the technology comprises the following steps: 1, adding one-hundred-million amphotericin B to a mixed solvent of dimethyl formamide and a 180% methanol solution, and adjusting the pH value of the resulting solution; 2, preprocessing a macroporous absorbent resin A and a macroporous absorbent resin B which have different polarities with the dimethyl formamide and ethanol, mixing the resin A with the resin B according to a resin A / resin B ratio of 3:4-5:6, packing the resulting mixed resin to a chromatographic column having a column length-diameter ratio of 12.5:1 through using a wet packing method to obtain a mixed resin column, allowing a filtrate obtained in step 1 to pass through the mixed resin column, mixing the filtrate passing through the mixed resin column with dichloromethane and injection water according to a ratio of the amphotericin B to the dichloromethane to the injection water of one hundred million:10-20ml:10-25ml, adjusting the pH of the resulting solution with an acid or an alkali to 4.0-6.0, crystallizing, maintaining the temperature at 35-45DEG C after crystal generation, and carrying out crystal growing through allowing crystals to stand for 18-24h; and 3, carrying out suction filtration on the solution obtained after the crystal growing, and drying at 40-60DEG C for 24-30h to obtain products. The technology solves problems of low yield, complex technology and high cost of traditional recrystallization methods, and solves disadvantages of use of a single resin to purify, long column passing time, large resin consumption amount, and unsatisfactory effect.

The invention relates to the technical field of medicaments, in particular to novel application of sodium houttuyfonate as a synergist of an antifungal medicament. The antifungal medicament is an azole or polyene antifungal medicament; and 1 to 16mu g of sodium houttuyfonate is added into each 1ml of antifungal medicament. Experiments prove that: when the sodium houttuyfonate is combined with the antifungal medicament such as fluconazole, ketoconazole, miconazole or amphotercin B, and the like, the treatment effect of the sodium houttuyfonate on superficial or deep fungal infection can be ensured under the condition of reducing the dosage and the sodium houttuyfonate can make the antifungal medicament recover the effect on medicament-resistant fungi, so the sodium houttuyfonate can be used as the synergist of the antifungal medicament. The sodium houttuyfonate serving as the synergist of the antifungal medicament can reduce the dosage of the azole or polyene antifungal medicament so as to reduce the toxic and side effects of the medicament; and particularly, the sodium houttuyfonate makes the antifungal medicament recover the effect on the medicament-resistant fungi, effectively treats fungal infection, particularly medicament-resistant fungal infection, and has important clinical application value.

The invention relates to the technical field of medicines, and in particular relates to an application of fructus cnidii coumarin in preparation of an antifungal medicament synergist product. External and internal experiences prove that fructus cnidii coumarin can remarkably improve the treatment effect on deep fungal infection by combination with fluconazole, and can restore effects of an antifungal medicament on medicament-resisting fungus, therefore the fructus cnidii coumarin can be used as a synergist of the antifungal medicament.

The invention relates to the technical field of medicines and discloses a new use of forsythiaside as a synergist of antifungal agents. In vivo and in vitro experiments show that the forsythiaside can be combined with the antifungal agents, such as fluconazole, itraconazole, miconazole, ketoconazole and the like, thereby improving the treatment effect of superficial and deep fungal infection with different degrees, leading the antifungal agents to recover the role to fungi with drug resistance and further using the forsythiaside as the synergist of the antifungal agents. The invention opens up the new use of the forsythiaside, and the use of the forsythiaside as the synergist of the antifungal agents can not only improve the antifungal role of drugs, but also lead the antifungal agents to recover the role to the fungi with drug resistance under the situations that the clinical drug resistance of the fungi is increasingly common and the drug resistance degree is increasingly serious, and further reduce the dosage of the antifungal agents, thereby saving medical expenses for patients and reducing toxicity and side effects of the drugs.

The present invention discloses a fungal DNA extraction method and a two-step PCR amplification technology for detecting clinical fungal infections. The method comprises simple DNA extraction method,design of specific primers for candida albicans, cryptococcus neoformans, and aspergillus fumigatus, and establishment of a detection method for simultaneously detecting the above three fungi. The method is sensitive and specific, and has important significance for clinical diagnosis of three fungal infections.

The invention relates to a pH-responsive amphotericin B derivative as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical chemistry preparation. According to the derivative of the invention, the amphotericin B derivative with a novel structure is obtained by modifying amino on trehalosamine in an amphotericin B molecule, and compared with non-modified amphotericin B, the amphotericin B derivative has the characteristics of low renal toxicity, small hemolysis and high safety. In addition, the invention further provides a preparation method of the derivative, the yield is high as well, and the prepared derivative has a good antifungal effect and has a wide market prospect in the aspect of treating systemic deep fungal infection.

The present invention provides an application of a terpene compound represented by a formula I in preparation of drugs for prevention and / or treatment of fungal infections. The compound represented by the formula I can be adopted as a novel antifungal active ingredient with characteristics of high efficiency and low toxicity so as to provide a good fungi inhibition effect, wherein drugs made from the compound further have characteristics of high efficiency and low toxicity, such that prevention and / or treatment of fungal infections, especially deep fungal infections can be achieved.

The invention relates to the technical field of medicines and discloses usage of Chinese roses for preparing an anti-fungal drug synergist product. By the aid of in vitro experiments, Chinese rose extract is applied in combination with antifungal drugs such as fluconazole, itraconazole and ketoconazole, so that therapeutic effects of superficial and deep fungal infection can be improved to different extents, and effects of anti-fungal drugs on drug-resistant fungi are restored. Therefore, Chinese roses can serve as the anti-fungal drug synergist product.

The invention discloses a method for collecting fungal spores in a deep fungal infection specimen, and belongs to the technical field of biology. The method comprises the following steps: (a) pretreatment: treating a deep fungal infection specimen, and collecting a mixture containing fungi and metabolites; (b) fungus culture: transferring the mixture into a fungus blood culture bottle by using a cell needle, and carrying out conventional fungus culture by using a blood culture instrument; and (c) collecting fungal spores: centrifuging the positive mixture in the fungal blood culture bottle, discarding the supernatant, transferring the precipitate into a 2 mL sterile EP tube internally provided with a biological filter membrane with a pore diameter of 10 [mu]m, centrifuging at a high speed,filtering, and collecting the fungal spores. Compared with a conventional method, the method has the advantages that pathogenic bacteria infected by invasive fungi can be quickly, efficiently and accurately collected, and the positive rate of culture is increased.

The invention relates to the technical field of medicines and discloses a new use of forsythiaside as a synergist of antifungal agents. In vivo and in vitro experiments show that the forsythiaside can be combined with the antifungal agents, such as fluconazole, itraconazole, miconazole, ketoconazole and the like, thereby improving the treatment effect of superficial and deep fungal infection withdifferent degrees, leading the antifungal agents to recover the role to fungi with drug resistance and further using the forsythiaside as the synergist of the antifungal agents. The invention opens up the new use of the forsythiaside, and the use of the forsythiaside as the synergist of the antifungal agents can not only improve the antifungal role of drugs, but also lead the antifungal agents torecover the role to the fungi with drug resistance under the situations that the clinical drug resistance of the fungi is increasingly common and the drug resistance degree is increasingly serious, and further reduce the dosage of the antifungal agents, thereby saving medical expenses for patients and reducing toxicity and side effects of the drugs.

The invention discloses a technology for purifying medicines for treating deep fungal infection. The technology is characterized in that the technology comprises the following steps: 1, adding one-hundred-million amphotericin B to a mixed solvent of dimethyl formamide and a 180% methanol solution, and adjusting the pH value of the resulting solution; 2, preprocessing a macroporous absorbent resin A and a macroporous absorbent resin B which have different polarities with the dimethyl formamide and ethanol, mixing the resin A with the resin B according to a resin A / resin B ratio of 3:4-5:6, packing the resulting mixed resin to a chromatographic column having a column length-diameter ratio of 12.5:1 through using a wet packing method to obtain a mixed resin column, allowing a filtrate obtained in step 1 to pass through the mixed resin column, mixing the filtrate passing through the mixed resin column with dichloromethane and injection water according to a ratio of the amphotericin B to the dichloromethane to the injection water of one hundred million:10-20ml:10-25ml, adjusting the pH of the resulting solution with an acid or an alkali to 4.0-6.0, crystallizing, maintaining the temperature at 35-45DEG C after crystal generation, and carrying out crystal growing through allowing crystals to stand for 18-24h; and 3, carrying out suction filtration on the solution obtained after the crystal growing, and drying at 40-60DEG C for 24-30h to obtain products. The technology solves problems of low yield, complex technology and high cost of traditional recrystallization methods, and solves disadvantages of use of a single resin to purify, long column passing time, large resin consumption amount, and unsatisfactory effect.

The invention relates to the technical field of medicines, in particular to application of tree peony bark to the preparation of a synergistic agent product for an antifungal medicine. The tree peony bark is the dried root bark of ranunculaceae plant peony (namely Paeonia suffruticosa Andr.) in 'Sheng Nong's herbal classic', and has a medicinal history of more than 2,000 years. In-vitro cell tests show that the tree peony bark has an inhibitory activity on various clinically separated candida albicans; when jointly used with a fluconazole antifungal agent, a tree peony bark extract can improve a therapeutic effect on superficial fungal infection and deep fungal infection to varying degrees and can recover an effect of the antifungal medicine on medicine-resistant fungi. Thus, the tree peony bark can be used as the synergistic agent for the antifungal medicine.

The present invention relates to a 2-triazolyl thiochromone compound (formula I), which has the following structure, wherein R1 is a five-membered triazolyl ring substituted by hydrogen or C1-C3 alkyl, R2 is hydroxyl, C1-C6 hydrocarbyloxy, C1-C6 hydrocarbylamino, C1-C6 hydrocarbonyl, phenyl, phenyl substituted by one or a plurality of C1-C6 hydrocarbyloxy, phenoxy and phenoxy substituted by one or a plurality of C1-C6 hydrocarbyloxy, R3, R4 and R6 are respectively and independently selected from hydrogen, fluorine, chlorine, bromine and iodine, and R5 is selected from hydrogen, fluorine, chlorine, bromine, iodine, C1-C6 hydrocarbyloxy, C1-C6 hydrocarbylamino, phenoxy, and phenoxy substituted by one or a plurality of C1-C6 hydrocarbonyl or hydrocarbyloxy. According to the present invention, the compound can be used for preparing antifungal drugs, provides strong antibacterial activity on common pathogenic fungi and deep fungal infections, and has advantages of low toxicity, good stability, and wide anti-fungal spectrum. The formula I is defined in the specification.

The invention discloses a novel panax stipuleanatus saponin analogue as well as a synthesis method and application thereof. Oleanolic acid, D-glucose and L-arabinose are used as initial raw materials to synthesize an oleanolic acid benzyl ester receptor, a glycosyl thioglycoside receptor and a glycosyl trifluoroacetimidate donor. The novel panax stipuleanatus saponin analogue, namely oleanolic acid 3-O-beta-D-glucopyranosyl-(1-> 3)-[alpha-L-furan arabinosyl-(1-> 4)]-beta-D-glucopyranosyl A, is obtained by performing glycosylation reaction on a receptor and a glycosyl donor to remove benzylidene, performing catalytic hydrogenation by 10% Pd / C and finally performing saponification in an alkaline solution. The method is short in route and high in yield. The novel panax stipuleanatus saponin analogue provided by the invention is combined with fluconazole to generate a synergistic effect of resisting drug-resistant candida albicans, and the problem of drug resistance of deep fungal infection is expected to be further solved.